Table 1:
Demographic and Clinical Characteristics of the Patients (n=1251)
| Demographic Characteristics | |
|---|---|
| Age (years; mean (SD)) | 57.00 (12.23) |
| Gender (% female (n)) | 78.0 (976) |
| Ethnicity (% (n)) | |
| White | 70.1 (866) |
| Black | 7.2 (89) |
| Asian/Pacific Islander | 12.2 (151) |
| Hispanic/Mixed/Other | 10.5 (130) |
| Education (years; mean (SD)) | 16.23 (3.00) |
| Married or partnered (% yes (n)) | 64.5 (795) |
| Lives alone (% yes (n)) | 21.7 (268) |
| Currently employed (% yes (n)) | 35.6 (441) |
| Child care responsibilities (% yes (n)) | 22.1 (271) |
| Income (% yes (n)) | |
| Less than $30,000 | 17.7 (199) |
| $30,000 to <$70,000 | 21.4 (240) |
| $70,000 to < $100,000 | 16.8 (189) |
| More than $100,000 | 44.0 (494) |
| Clinical Characteristics | |
| Number of comorbidities (mean (SD)) | 2.39 (1.43) |
| Self-administered Comorbidity Questionnaire score (mean (SD)) | 5.46 (3.22) |
| Body mass index (kg/m2; mean (SD)) | 26.24 (5.69) |
| Karnofsky Performance Status score (mean (SD)) | 80.14 (12.33) |
| Have you ever considered yourself a smoker (% yes (n)) | 34.7 (427) |
| Exercise on a regular basis (% yes (n)) | 71.0 (868) |
| Cancer diagnosis (% yes (n)) | |
| Breast | 40.2 (503) |
| Gastrointestinal | 30.7 (384) |
| Gynecological | 17.8 (223) |
| Lung | 11.3 (141) |
| Time since cancer diagnosis (years; mean (SD)) | 1.96 (3.84) |
| Time since cancer diagnosis (years; median) | 0.42 |
| Any prior cancer treatments (% yes (n)) | 75.2 (935) |
| Number prior cancer treatments (mean (SD)) | 1.59 (1.50) |
| Chemotherapy cycle length (% (n)) | |
| 14 days | 42.2 (528) |
| 21 days | 50.4 (631) |
| 28 days | 7.3 (91) |
| Emetogenicity of CTX regimen (% (n)) | |
| Minimal/Low | 19.6 (245) |
| Moderate | 60.6 (758) |
| High | 19.8 (248) |
| Antiemetic regimen (% (n)) | |
| None | 6.9 (86) |
| Steroid alone or serotonin receptor antagonist alone | 20.1 (252) |
| Serotonin receptor antagonist & steroid | 46.5 (582) |
| NK-1 receptor antagonist & two other antiemetics | 24.1 (301) |
| Presence of metastatic disease (% yes (n)) | 67.7 (841) |
| Number of metastatic sites including lymph node involvement (mean (SD)) | 1.25 (1.23) |
| Number of metastatic sites excluding lymph node involvement (mean (SD)) | 0.79 (1.05) |
Abbreviations: CTX = chemotherapy; kg/m2 = kilograms per meters squared; NK-1 = neurokinin-1; SD = standard deviation